25I-NB3OMe
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C18H22INO3 |
Molar mass | 427.282 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
25I-NB3OMe (2C-I-NB3OMe, NB3OMe-2C-I) is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT2A receptor.[1][2]
Legality
United Kingdom
This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[3]
United States
25I-NB3OMe is not a controlled substance, but is a positional isomer of 25I-NBOMe and thus may be considered a Schedule I drug under the Federal Analogue Act, meaning that it would be subject to the same penalties for possession, distribution, and manufacture as 25I-NBOMe.
References
- ↑ https://bitnest.netfirms.com/external.php?id=%2501%253B5%25168%250F%2518%250DG%257F%255B18%2521UYHZP%251CUTscc%250BWk%5B%5D
- ↑ https://bitnest.netfirms.com/external.php?id=%2501%253B5%25168%250F%2518%250DG%257F%255B18%2521UYHRO%2500JAsca%2515%255C%5B%5D
- ↑ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". www.legislation.gov.uk.
Serotonin receptor modulators | |||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
|
Phenethylamines |
|
---|---|
Amphetamines |
|
Phentermines |
|
Cathinones |
|
Phenylisobutylamines | |
Phenylalkylpyrrolidines | |
Catecholamines (and close relatives) |
|
Miscellaneous |
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.